Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
TNGX Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TNGX Stock 12 Month Forecast
Average Price Target
$13.67
▲(41.95% Upside)
| Highest Price Target$15.00 | Average Price Target$13.67 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Stifel Nicolaus
$15
Buy
55.76%
Upside
Initiated
12/04/25
Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics' VopimetostatWe initiate coverage of Tango Therapeutics (TNGX) with a Buy rating and $15 target price. We view vopimetostat (vopi) as a potential best-in-class PRMT5 inhibitor, with a key thesis driver being management’s strategic positioning of vopi to become standard of care in MTAPnull 2L PDAC (post-RAS inhibitor); Ph3 in 2L PDAC to initiate in 2026. We model vopi approval in 2L PDAC by 1Q29, reaching peak global revenue of ~$1.2B by 2035 (assuming ~40% U.S. 2L market penetration). We believe these estimates could be conservative and view longer follow-up of 2L PDAC data in 2026 as further de-risking. The ongoing Ph1/2 study in combination with RVMD's RAS(ON) inhibitors could unlock additional potential upside in 1L PDAC (first combo data in 2026). Cash runway into 2028.
B. Riley Securities
$8→$14
Buy
45.38%
Upside
Reiterated
11/17/25
H.C. Wainwright
$13
Buy
34.99%
Upside
Reiterated
11/05/25
Barclays
$13
Buy
34.99%
Upside
Reiterated
11/04/25
Guggenheim
$10→$12
Buy
24.61%
Upside
Reiterated
10/23/25
Piper Sandler
$11
Buy
14.23%
Upside
Reiterated
08/29/25
Leerink Partners
$10
Buy
3.84%
Upside
Reiterated
08/06/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
$15
Buy
55.76%
Upside
Initiated
12/04/25
Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics' VopimetostatWe initiate coverage of Tango Therapeutics (TNGX) with a Buy rating and $15 target price. We view vopimetostat (vopi) as a potential best-in-class PRMT5 inhibitor, with a key thesis driver being management’s strategic positioning of vopi to become standard of care in MTAPnull 2L PDAC (post-RAS inhibitor); Ph3 in 2L PDAC to initiate in 2026. We model vopi approval in 2L PDAC by 1Q29, reaching peak global revenue of ~$1.2B by 2035 (assuming ~40% U.S. 2L market penetration). We believe these estimates could be conservative and view longer follow-up of 2L PDAC data in 2026 as further de-risking. The ongoing Ph1/2 study in combination with RVMD's RAS(ON) inhibitors could unlock additional potential upside in 1L PDAC (first combo data in 2026). Cash runway into 2028.
B. Riley Securities
$8→$14
Buy
45.38%
Upside
Reiterated
11/17/25
H.C. Wainwright
$13
Buy
34.99%
Upside
Reiterated
11/05/25
Barclays
$13
Buy
34.99%
Upside
Reiterated
11/04/25
Guggenheim
$10→$12
Buy
24.61%
Upside
Reiterated
10/23/25
Piper Sandler
$11
Buy
14.23%
Upside
Reiterated
08/29/25
Leerink Partners
$10
Buy
3.84%
Upside
Reiterated
08/06/25
Best Analysts Covering Tango Therapeutics
1 Month
xxx
Success Rate
12/19 ratings generated profit
Average Return
+5.03%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +5.03% per trade.
3 Months
xxx
Success Rate
11/16 ratings generated profit
Average Return
+54.01%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +54.01% per trade.
1 Year
Success Rate
11/16 ratings generated profit
Average Return
+117.72%
reiterated a buy rating last month
Copying Peter Lawson's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +117.72% per trade.
2 Years
xxx
Success Rate
13/16 ratings generated profit
Average Return
+119.64%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +119.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TNGX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
8
6
10
8
8
Buy
0
1
1
1
0
Hold
11
7
7
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
14
18
15
14
Each month's total comprises the sum of three months' worth of ratings.
TNGX Financial Forecast
TNGX Stock Forecast FAQ
What is TNGX’s average 12-month price target, according to analysts?
Based on analyst ratings, Tango Therapeutics’s 12-month average price target is 13.67.
What is TNGX’s upside potential, based on the analysts’ average price target?
Tango Therapeutics has 41.95% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TNGX a Buy, Sell or Hold?
Tango Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Tango Therapeutics’s price target?
The average price target for Tango Therapeutics is 13.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $12.00. The average price target represents 41.95% Increase from the current price of $9.63.
The highest analyst price target is $15.00 ,the lowest forecast is $12.00. The average price target represents 41.95% Increase from the current price of $9.63.
What do analysts say about Tango Therapeutics?
Tango Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of TNGX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.